Divi's Lab

₹5880.5 96.7 | 1.7%

WEBSITE BSE:532488 NSE : DIVI'S LAB. 26 Dec, 16:01

Market Cap ₹156107 Cr.

Stock P/E 97.6

P/B 11.4

Current Price ₹5880.5

Book Value ₹ 516.7

Face Value 2

52W High ₹6448.8

Dividend Yield 0.51%

52W Low ₹ 3350.1

Edit Ratio

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Laboratories Ltd manufactures Active Pharma Ingredients (APIs) and intermediates. The organization in a matter of short time multiplied their breadth of operations to offer whole turnkey solutions to the domestic Indian pharmaceutical enterprise.They are actively concerned in growing trade, patent non-infringing approaches for APIs, for the inventors to control late life cycle and leading customary drug producers.The company's product variety includes Bupropion Hbr,Bupropion HCL,Capecitabine,Carbidopa,Desloratadine,Dexlansoprazole /(R)-Lansoprazole, Irbesartan, Levodopa, Niacin, Sibutramine HCL, Valacyclovir HCL, Valsartan, Venlafaxine HCL, VerapamiL HCL, Vigabatrin, Zolpidem Tartrate ,and so forth.

Divi's Lab Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Divi's Lab Quarterly Results

#(Fig in Cr.)	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Net Sales	2255	1855	1708	1951	1778	1909	1855	2303	2118	2338
Other Income	88	80	113	66	81	86	95	79	79	106
Total Income	2343	1935	1821	2017	1859	1995	1950	2382	2197	2444
Total Expenditure	1407	1234	1299	1464	1274	1430	1366	1572	1496	1622
Operating Profit	936	701	522	553	585	565	584	810	701	822
Interest	0	0	0	0	0	1	0	2	0	1
Depreciation	84	86	87	87	93	95	95	95	97	99
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	852	615	435	466	492	469	489	713	604	722
Provision for Tax	150	122	129	145	136	121	131	175	174	212
Profit After Tax	702	493	306	321	356	348	358	538	430	510
Adjustments	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	702	493	306	321	356	348	358	538	430	510
Adjusted Earnings Per Share	26.4	18.6	11.5	12.1	13.4	13.1	13.5	20.3	16.2	19.2

Divi's Lab Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Net Sales	2532	3115	3776	4064	3891	4946	5394	6969	8960	7767	7845	8614
Other Income	71	45	97	75	113	156	190	63	116	345	339	359
Total Income	2603	3160	3874	4139	4005	5102	5584	7032	9076	8112	8184	8973
Total Expenditure	1517	1949	2358	2617	2629	3073	3571	4108	5079	5398	5639	6056
Operating Profit	1086	1211	1516	1522	1376	2029	2013	2924	3997	2714	2545	2917
Interest	3	3	5	3	2	5	7	2	2	2	4	3
Depreciation	92	136	118	123	142	169	186	256	312	343	378	386
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	0	0	0	0
Profit Before Tax	991	1072	1393	1395	1231	1855	1819	2666	3684	2369	2163	2528
Provision for Tax	218	221	267	335	354	502	443	682	723	545	563	692
Profit After Tax	773	852	1126	1060	877	1353	1377	1984	2960	1824	1600	1836
Adjustments	0	0	0	0	0	0	0	0	0	0	0	0
Profit After Adjustments	773	852	1126	1060	877	1353	1377	1984	2960	1824	1600	1836
Adjusted Earnings Per Share	29.1	32.1	42.4	39.9	33	51	51.9	74.8	111.5	68.8	60.4	69.2

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	1%	4%	10%	12%
Operating Profit CAGR	-6%	-5%	5%	9%
PAT CAGR	-12%	-7%	3%	8%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	52%	10%	26%	21%
ROE Average	12%	18%	20%	22%
ROCE Average	16%	24%	26%	28%

Divi's Lab Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	2963	3495	4293	5357	5925	6957	7310	9295	11728	12767	13571
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	2	1	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	648	841	85	1412	1769	991	295	364	437	557	611
Total Current Liabilities	627	776	520	659	653	847	1821	1728	2454	1539	1755
Total Liabilities	4241	5112	4898	7429	8347	8795	9425	11387	14619	14863	15937
Fixed Assets	1222	1309	1439	1559	1996	2088	2782	3704	4325	4722	4739
Other Non-Current Assets	763	1031	432	1859	1816	2057	1070	892	684	391	1046
Total Current Assets	2256	2772	3027	4011	4535	4650	5574	6791	9610	9750	10152
Total Assets	4241	5112	4898	7429	8347	8795	9425	11387	14619	14863	15937

Divi's Lab Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	12	15	18	-17	-4	-21	2	43	2030	1215	170
Cash Flow from Operating Activities	557	826	1038	1150	776	954	1216	1947	1912	2459	1261
Cash Flow from Investing Activities	-305	-521	-406	-1140	-478	-685	-83	75	-2195	-2707	-269
Cash Flow from Financing Activities	-248	-303	-631	2	-314	-246	-1091	-35	-532	-797	-799
Net Cash Inflow / Outflow	3	3	0	13	-17	23	41	1987	-816	-1045	193
Closing Cash & Cash Equivalent	15	18	18	-4	-21	2	43	2030	1215	170	363

Divi's Lab Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	29.13	32.08	42.41	39.95	33.04	50.96	51.86	74.75	111.53	68.83	60.38
CEPS(Rs)	32.6	37.2	46.86	44.59	38.41	57.32	58.87	84.38	123.26	81.77	74.64
DPS(Rs)	20	20	10	10	10	16	16	20	30	30	30
Book NAV/Share(Rs)	111.63	131.67	161.73	201.82	223.2	262.09	275.38	350.15	441.82	481.77	512.11
Core EBITDA Margin(%)	39.81	37.12	37.28	35.24	32.27	37.6	33.41	40.92	43.18	30.3	27.96
EBIT Margin(%)	38.97	34.21	36.73	34.06	31.53	37.33	33.48	38.16	41	30.32	27.46
Pre Tax Margin(%)	38.85	34.12	36.61	33.98	31.47	37.24	33.35	38.13	40.98	30.3	27.41
PAT Margin (%)	30.32	27.1	29.59	25.82	22.41	27.15	25.23	28.38	32.94	23.33	20.28
Cash Profit Margin (%)	33.93	31.43	32.69	28.83	26.06	30.54	28.64	32.04	36.4	27.71	25.07
ROA(%)	19.92	18.21	22.49	17.21	11.12	15.78	15.11	19.07	22.77	12.37	10.39
ROE(%)	28.31	26.37	28.91	21.98	15.55	21	19.3	23.9	28.16	14.89	12.15
ROCE(%)	36.04	33.06	35.57	28.75	21.68	28.5	25.36	32.07	35.06	19.36	16.46
Receivable days	88.42	85.12	77.83	79.19	89.33	79.78	86.18	80.66	83.26	98.42	91.33
Inventory Days	126.52	121.69	113.7	112.34	124.56	114.41	121.62	104.66	100.99	136.04	143.02
Payable days	62.32	56.95	55.71	80.72	101.95	90.34	93.73	106.32	95.88	93.12	92.5
PER(x)	23.5	27.9	23.23	15.62	32.98	33.42	38.33	48.56	39.49	41.05	56.92
Price/Book(x)	6.13	6.8	6.09	3.09	4.88	6.5	7.22	10.37	9.97	5.87	6.71
Dividend Yield(%)	1.46	1.12	1.02	1.6	0.92	0.94	0.81	0.55	0.68	1.06	0.87
EV/Net Sales(x)	7.17	7.62	6.92	4.07	7.42	9.14	9.76	13.52	12.73	9.1	11.1
EV/Core EBITDA(x)	16.71	19.59	17.23	10.86	20.98	22.28	26.17	32.22	28.54	26.04	34.22
Net Sales Growth(%)	18.06	23.02	21.23	7.63	-4.25	27.1	9.06	29.2	28.56	-13.31	1
EBIT Growth(%)	26.8	8.16	30.01	0.08	-11.8	50.75	-1.78	46.07	38.13	-35.67	-8.6
PAT Growth(%)	28.46	10.11	32.21	-5.81	-17.3	54.24	1.76	44.15	49.19	-38.39	-12.28
EPS Growth(%)	28.46	10.11	32.21	-5.8	-17.3	54.24	1.76	44.15	49.19	-38.28	-12.28
Debt/Equity(x)	0.01	0.01	0.01	0.01	0.01	0.02	0	0	0	0	0
Current Ratio(x)	3.6	3.57	5.83	6.08	6.94	5.49	3.06	3.93	3.92	6.34	5.78
Quick Ratio(x)	2.11	2.08	3.5	4.08	4.87	3.4	2.04	2.69	2.76	4.39	3.97
Interest Cover(x)	336.24	373.59	294.75	416.28	520.55	397.38	255.83	1270.54	1842.75	1185.5	541.75
Total Debt/Mcap(x)	0	0	0	0	0	0	0	0	0	0	0

Divi's Lab Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	51.94	51.94	51.94	51.94	51.93	51.93	51.92	51.92	51.9	51.89
FII	16.52	15.4	15.14	14.67	14.7	14.6	14.86	14.68	16.16	17.25
DII	19.98	20.78	20.67	21.08	21.23	21.75	21.88	22.21	21.77	21.06
Public	11.56	11.88	12.24	12.31	12.14	11.73	11.34	11.19	10.18	9.8
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	13.79	13.79	13.79	13.79	13.79	13.79	13.78	13.78	13.78	13.78
FII	4.39	4.09	4.02	3.89	3.9	3.88	3.94	3.9	4.29	4.58
DII	5.3	5.52	5.49	5.59	5.64	5.77	5.81	5.9	5.78	5.59
Public	3.07	3.15	3.25	3.27	3.22	3.11	3.01	2.97	2.7	2.6
Others	0	0	0	0	0	0	0	0	0	0
Total	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55	26.55

Pros

Debtor days have improved from 93.12 to 92.5days.
Company is almost debt free.

Cons

Stock is trading at 11.4 times its book value.
The company has delivered a poor profit growth of 3% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Divi's Lab News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Divi's Lab

Add Watchlist

Divi's Lab Research see more...

Overview Inc. Year: 1990Industry: Pharmaceuticals & Drugs

Divi's Lab Share Price

Alert Data

Quarterly Price

Peer Comparison

Divi's Lab Quarterly Results

Divi's Lab Profit & Loss

Growth Rates

Divi's Lab Balance Sheet

Divi's Lab Cash Flow

Divi's Lab Ratios

Divi's Lab Shareholding Pattern

Divi's Lab News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!